Ecaterina Dumbrava, MD, discusses early findings of rezatapopt in patients with solid tumors harboring TP53 Y220C mutations.
Ecaterina Ileana Dumbrava, MD
Advertisement
Ecaterina Ileana Dumbrava, MD is anAssistant Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
Articles by Ecaterina Ileana Dumbrava, MD
Ecaterina Dumbrava, MD, discusses the rationale and clinical development of rezatapopt in ovarian cancer and other solid tumors harboring TP53 Y220C mutations.
Ecaterina Ileana Dumbrava, MD, discusses the mechanism of action of BDC-1001 in advanced HER2-expressing breast cancer.
Advertisement
Latest Updated Articles
Dr. Dumbrava on the Mechanism of Action of BDC-1001 in Advanced HER2-Expressing Breast CancerPublished: January 26th 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
3
Multidisciplinary Breast Cancer Experts Outline Proactive Strategies for Managing Treatment-Related Toxicities: With Neil Iyengar, MD; Heather Moore, CPP, PharmD; and Sarah Donahue, MPH, NP
4
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
5